Fig. 6: The combination of PIC + RT + anti-CTLA-4 (C4) improves tumor response and survival in both the MyC-CaP prostate and TC11 breast tumor models. | Nature Communications

Fig. 6: The combination of PIC + RT + anti-CTLA-4 (C4) improves tumor response and survival in both the MyC-CaP prostate and TC11 breast tumor models.

From: Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade

Fig. 6

a Scheme for the studies. b Average tumor growth curves of MyC-CaP prostate tumors and c survival rate of mice after the indicated treatments. (n = 8 biologically independent animals). d Individual tumor growth curves in b. e Average tumor growth curves of TC11 tumor and f survival rate of mice after the indicated treatments (control: n = 11; PIC + RT + C4: n = 12; others: n = 10 biologically independent animals). g Individual tumor growth curves in e. CR: complete response. C4: anti-CTLA-4. i.p.: intraperitoneal injection. For MyC-CaP prostate cancer model, tumor was implanted on the right flank of mice. For TC11 breast cancer model, tumor was implanted on the right mammary fat pad of mice. PIC: 140 μg/100μL/dose. C4: 100 μg/100 μL/dose. Data in b and e are shown as mean ± SD. Statistical significance was calculated via linear mixed effects modeling in b and e, and log-rank test in c and f. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Source data are provided in Source Data file.

Back to article page